Cyclophosphamide
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Kite, A Gilead CompanySmall moleculePhase 1Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 35/ 100
- Competitive Position
- 89/ 100
Competitive context
4 Active assets in the Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Kite, A Gilead Company | Phase 1 | CCC |
Universal Cd19 Car-Γδt Cell Tongji Hospital | Phase 1 | CC |
Bcma Targeted Car T-Cells Tongji Hospital | Early Phase 1 | C |
cd19/bcma-targeted car-t cells Tongji Hospital | Early Phase 1 | C |
Same molecule, other indications
Cyclophosphamide is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →